Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of BRCA testing on cytologic samples of high-grade serous carcinoma.

Cancer cytopathology - 1 Nov 2021

Lou Si Kei, Grenier Sylvie, Care Melanie, McCuaig Jeanna, Stockley Tracy L, Clarke Blaise, Ruff Heather M, Boerner Scott L

Abstract excerpt

BACKGROUND: Testing for BRCA1/2 gene alterations in patients with high-grade serous carcinoma (HGSC) is a critical determinant of treatment eligibility for poly(adenosine diphosphate-ribose) polymerase inhibitors in addition to providing vital information for genetic counselling. Many patients present with effusions necessitating therapeutic drainage, and this makes cytologic specimens (CySs) the initial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Carcinoma

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 34157791
DOI: 10.1002/cncy.22484

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of BRCA testing on cytologic samples of high-grade serous carcinoma.PMID 34157791Read ↗

Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinomaSemantic proximity Read ↗

Exploring alternatives to tumor tissue for BRCA1/2 next-generation sequencing testing in high-grade serous ovarian cancer: A 34-case series of malignant ascites.Semantic proximity Read ↗

Cytopathological assessment is an accurate method for identifying immunophenotypic features and BRCA1/2 mutations of high-grade serous carcinoma from ascites.Semantic proximity Read ↗

High-grade serous ovarian carcinoma and detection of inactivated BRCA genes from biopsy material of Slovak patients.Semantic proximity Read ↗

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.Semantic proximity Read ↗

Impact of serous fluid volume on next-generation sequencing: a significant step forward for optimization of serous fluid sample collection.Semantic proximity Read ↗

Molecular profiling of breast cancer pleural effusions using cytology specimens: Impact of sample source and cytological features on next-generation sequencing performance.Semantic proximity Read ↗

Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population-based testing program.Semantic proximity Read ↗

High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.Semantic proximity Read ↗

Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysisSemantic proximity Read ↗

Molecular characteristics of low-grade serous carcinoma in effusions.Semantic proximity Read ↗

Low-grade serous carcinoma detected from intraoperative peritoneal washings: Cytological findings and detection of KRAS mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.